When heart patients are diagnosed with severe AS, how quickly do they need to undergo TAVR? That was the focus of a new analysis published in Open Heart.
Accessing cardiology data for research or population health initiatives is still quite difficult in Europe. Could this new project help reverse that trend?
The calcified plaque-shattering technology developed by Shockwave Medical continues to gain momentum. As more care teams start using IVL during PCI, researchers are paying close attention to its long-term impact on patient care.
Researchers hoped to gain a better understanding of the device's real-world impact by reviewing registry data from more than 97,000 U.S. patients. Overall, the Watchman FLX was linked to positive data and limited adverse events one year after treatment.
The J Valve from JC Medical was linked to positive outcomes and “excellent” hemodynamic data after 30 days in an early feasibility study published in JACC: Cardiovascular Interventions. Researchers noted that the valve showed potential in patients with large aortic annuli, which represents an "unmet critical need" at this stage.
Finerenone, sold under the brand name Kerendia, is already approved by the FDA for reducing heart and kidney risks in patients with chronic kidney disease (CKD) and type 2 diabetes. Bayer plans on presenting the new data in full at ESC Congress 2024 in London.
Cardiac researcher Masoud Pezeshkian, MBBS, became one of the world's most widely known cardiac surgeons in the world when he officially became Iran's president.
Most EP clinical study data are from men, Anne Kroman, DO, explained in an interview. This is a significant problem, she said, because heart rhythm issues look quite different in women.
Even grafts that represent the current gold standard for bypass surgeries are associated with high failure rates, researchers noted. They think these 3D-printed blood vessels could provide considerable value.
![Left atrial appendage occlusion (LAAO) with the Watchman FLX device from Boston Scientific is associated with positive outcomes and limited adverse events after one year, according to new findings published in Circulation: Cardiovascular Interventions.[1] Many prior Watchman FLX studies, including PINNACLE FLX, had focused on the device’s performance in a controlled setting. The study’s authors hoped to gain a better understanding of its real-world impact by reviewing registry data from more than 97,000 U.S](/sites/default/files/styles/240x220/public/2024-08/screenshot_2024-08-12_at_11.35.13_am.png.webp?itok=YxsSJPAl)
![Researchers have developed artificial blood vessels that could be as strong and durable as the real things, publishing their work in Advanced Materials Technologies.[1] The group hopes its work could go on to make a significant impact in care for heart bypass patients.](/sites/default/files/styles/240x220/public/2024-07/screenshot_2024-07-25_at_2.38.35_pm.png.webp?itok=Kv-BN0d2)